In August 2023, the results of a landmark clinical trial called SELECT were published in the New England Journal of Medicine, and they quietly shifted how the medical community thinks about semaglutide. Not as a diabetes drug being repurposed for weight loss, but as a cardiovascular medication that also produces significant weight loss. For patients considering or currently taking Ozempic, understanding what SELECT found and why it matters gives important context for the broader value of this treatment.<\/p>\n
Most of the major GLP-1 trials before SELECT, including LEADER with liraglutide and SUSTAIN-6 with semaglutide, enrolled patients with type 2 diabetes. The cardiovascular benefits observed in those trials were real and significant, but they left an open question: were the heart benefits coming from better blood sugar control, from weight loss, from direct anti-inflammatory effects of the drug, or some combination of all three?<\/p>\n
SELECT was designed specifically to answer that question in a population without diabetes. The trial enrolled over 17,600 adults who had established cardiovascular disease and a BMI of 27 or higher, but who did not have type 2 diabetes. Half received weekly semaglutide 2.4 mg injections (the Wegovy dose), and half received placebo, with both groups continuing their standard cardiovascular care.<\/p>\n
The primary endpoint was a composite of major adverse cardiovascular events: cardiovascular death, non-fatal heart attack, and non-fatal stroke. This is the hardest, most clinically meaningful outcome you can measure in a cardiovascular trial.<\/p>\n
After an average follow-up of approximately 34 months, semaglutide reduced the primary composite cardiovascular endpoint by 20 percent compared to placebo. That’s a statistically significant and clinically meaningful result. To put it in concrete terms, for every 100 patients with established cardiovascular disease treated with semaglutide over roughly three years, approximately 20 cardiovascular events that would have occurred in the placebo group were prevented.<\/p>\n
The reduction was consistent across the individual components of the composite endpoint. Cardiovascular death was reduced, non-fatal heart attacks were reduced, and non-fatal strokes were reduced. The benefit appeared across subgroups defined by age, sex, BMI, geographic region, and baseline cardiovascular risk.<\/p>\n
Importantly, the benefit emerged before patients had lost substantial amounts of weight. This timing suggests the cardiovascular protection isn’t purely a downstream effect of fat reduction. Something about semaglutide’s direct effects on the vasculature, inflammation, and metabolic signaling appears to contribute independently.<\/p>\n
The SELECT trial’s restriction to patients without diabetes is what makes it scientifically distinctive. Previous cardiovascular outcome trials with GLP-1 medications couldn’t separate the effects of glucose lowering from the effects of weight loss and direct drug mechanisms, because both were happening simultaneously in diabetic patients.<\/p>\n
In SELECT, glucose lowering wasn’t a meaningful factor because participants didn’t have diabetes to begin with. The cardiovascular benefit observed had to be coming from somewhere else: weight loss, reduced inflammation, direct vascular effects, or some combination. This implication is significant because it means the cardiovascular benefits of semaglutide are not contingent on having diabetes. They appear accessible to the broader population of people with obesity and cardiovascular risk.<\/p>\n
The article on how GLP-1 medications affect blood pressure over time<\/a> covers one of the specific cardiovascular mechanisms, blood pressure reduction, that likely contributed to the SELECT outcomes and is worth understanding alongside the trial results.<\/p>\n The SELECT results contributed to a significant regulatory and clinical shift. In March 2024, the FDA approved Wegovy specifically for reduction of cardiovascular risk in adults with obesity or overweight and established cardiovascular disease, making it the first weight loss medication to carry an approved cardiovascular indication in the United States.<\/p>\n This matters practically because it changes the insurance coverage conversation. Many payers who previously declined to cover semaglutide for weight loss have faced pressure to reconsider coverage for patients who meet the cardiovascular risk criteria established by SELECT. The medication is no longer solely a weight loss drug from a regulatory standpoint. It’s a cardiovascular risk reduction drug that also produces weight loss.<\/p>\n For patients who have been denied coverage for Ozempic or Wegovy on the grounds that weight loss medications aren’t covered, the SELECT data and the subsequent FDA approval of Wegovy’s cardiovascular indication provide new grounds for appeal.<\/p>\n One of the more scientifically interesting threads running through the SELECT data is the inflammation story. Semaglutide produced significant reductions in high-sensitivity CRP (hsCRP), a sensitive marker of systemic inflammation, in SELECT participants. Those reductions appeared early in the trial, before substantial weight loss had occurred, and correlated with cardiovascular benefit.<\/p>\n This connects to what researchers have observed in other contexts. Atherosclerosis, the underlying process driving most heart attacks and strokes, is fundamentally inflammatory. Plaques build up in artery walls through a process involving macrophage infiltration, oxidized LDL accumulation, and chronic low-grade inflammation. A medication that reduces systemic inflammatory markers may be slowing that process directly, not just indirectly through weight loss.<\/p>\nWhat SELECT Means for How Semaglutide Is Prescribed<\/h2>\n
The Inflammation Connection<\/h2>\n